Pfizer reported third-quarter 2026 revenue of $16.6 billion on Tuesday, 3 November 2026, beating Wall Street expectations and raising its full-year guidance, as growth in its core medicines more than offset the continued fading of its Covid-era products. The Pfizer Q3 2026 earnings report arrived on Election Day in the United States, during a falling global market. Headline revenue was broadly flat against a year earlier, but the detail underneath was stronger: excluding Covid products, revenue grew, adjusted earnings beat the consensus by a wide margin, and management lifted both its revenue and profit outlook for the full year.

That combination matters because Pfizer is one of the world's largest drugmakers, and its results are watched as a gauge of prescription demand, the strength of its cardiology and oncology portfolios, and how far the industry has moved beyond the pandemic boom. Tuesday's report suggested that transition is further advanced than feared, even as reported profit fell.

Key Points

• Pfizer reported third-quarter 2026 revenue of $16.583 billion, broadly flat against $16.654 billion a year earlier and above analyst expectations of about $15.87 billion.
• Adjusted diluted earnings per share were $0.87, flat year over year but well above the roughly $0.73 consensus, while reported diluted earnings per share fell 9% to $0.56.
• Excluding Comirnaty and Paxlovid, revenue grew 7% operationally, and revenue from launched and acquired products grew 32% operationally.
• Eliquis revenue rose $513 million, or 25%, and Padcev rose $255 million, or 55%, operationally, partly offset by a $771 million fall in Paxlovid and a $339 million fall in Comirnaty.
• Pfizer raised full-year 2026 revenue guidance to $62.0 billion to $64.0 billion and adjusted diluted earnings per share guidance to $2.95 to $3.05.

What Happened

Pfizer published its third-quarter results before the United States market opened on Tuesday. Revenue of $16.583 billion was almost unchanged from the $16.654 billion reported in the same quarter of 2025. Analysts had expected about $15.87 billion, so Pfizer beat that forecast by roughly $700 million, a comfortable margin that showed demand across its core portfolio held up better than the market had assumed.

Profit told a similar two-sided story. Reported net income fell 8% to $3.242 billion, and reported diluted earnings per share fell 9% to $0.56. Adjusted diluted earnings per share, which strips out items Pfizer says do not reflect underlying operating performance, were $0.87, unchanged from a year earlier but well above the consensus of about $0.73. On that adjusted basis, which investors often use for comparison, Pfizer delivered a clear beat.

The company also confirmed a leadership change. Cecile Guegan became permanent chief financial officer effective 1 November 2026, after serving as interim chief financial officer since 16 August. The appointment removes uncertainty at the top of the finance function at a moment when Pfizer is asking investors to focus on longer-term growth, its pipeline and cost discipline rather than short-term Covid volatility.

Background and Context

Pfizer's recent history cannot be understood without the Covid pandemic. Comirnaty, its Covid vaccine, and Paxlovid, its Covid antiviral, generated enormous revenue in 2021 and 2022 and then declined sharply as infection rates fell and governments stopped bulk purchasing. That decline has distorted reported growth for several years, forcing investors to look at performance excluding those two products to judge the rest of the business.

Tuesday's report showed why that distinction matters. Excluding Comirnaty and Paxlovid, revenue grew 7% operationally, stripping out currency effects to give a cleaner view of volume and pricing. That suggests the non-Covid business is expanding, not merely stable. Revenue from launched and acquired products grew 32% operationally.

Pfizer Q3 2026 Earnings: Growth Beyond Covid

The product breakdown explains the headline beat. Eliquis, the blood thinner used to reduce the risk of stroke and blood clots, saw revenue rise by $513 million, or 25%, a large absolute increase that underlines its continued importance. Padcev, a cancer treatment, rose by $255 million, or 55%, operationally, a rapid rate that reflects expanding use in oncology, one of the most competitive areas of modern medicine.

Those gains were partly offset by expected Covid declines. Paxlovid revenue fell by $771 million, or 63%, and Comirnaty revenue fell by $339 million, or 29%. Together they removed more than $1.1 billion from the year-over-year comparison, which is why reported revenue was flat despite strong growth elsewhere. Without those declines, Pfizer's quarter would have shown clear headline growth.

The raised guidance is the other key element. Pfizer lifted full-year revenue guidance to $62.0 billion to $64.0 billion, up from $60.5 billion to $62.5 billion, an increase of $1.5 billion at both ends of the range. Adjusted diluted earnings guidance was raised to $2.95 to $3.05, up from $2.80 to $3.00. Raising both revenue and profit guidance late in the year carries weight, because there is less time for conditions to change before the year ends.

Reactions and Market Context

The beat against expectations was the most immediate positive: revenue about $700 million above consensus and adjusted earnings about $0.14 per share above consensus are material margins, not rounding differences. They reduce the risk that Pfizer will need to lower expectations later in the year. The wider market context was less favourable, with global markets falling on Tuesday as technology stocks extended a retreat over doubts about how quickly heavy artificial intelligence spending will pay off, and the Nasdaq 100 entering correction territory.

Why It Matters

For patients, growth in medicines such as Eliquis and Padcev reflects wider use of treatments for heart disease, stroke prevention and cancer. For investors, the results test whether Pfizer's post-Covid strategy is working: whether newer and acquired products can replace Covid revenue, whether costs are under control, and whether the company can return to sustained growth.

What Happens Next

The immediate focus will be the fourth quarter and whether Pfizer can deliver the full-year outcome implied by its new guidance. Fourth-quarter results, due early in 2027, will be judged against revenue guidance of $62.0 billion to $64.0 billion and adjusted earnings guidance of $2.95 to $3.05 per share. Investors will also watch whether Eliquis and Padcev growth holds.

For wider market context, see our global markets slide on Election Day and our US stock futures report ahead of the open.

Frequently Asked Questions

How much revenue did Pfizer report in Q3 2026?
Pfizer reported $16.583 billion, broadly flat against $16.654 billion a year earlier but above analyst expectations of about $15.87 billion.

What were Pfizer's adjusted earnings per share?
Adjusted diluted earnings per share were $0.87, flat year over year but well above the roughly $0.73 consensus. Reported diluted earnings per share fell 9% to $0.56.

Why was reported revenue flat if the underlying business grew?
Because Covid products fell sharply: Paxlovid dropped $771 million and Comirnaty dropped $339 million. Excluding those two products, revenue grew 7% operationally.

What is Pfizer's new full-year guidance?
Revenue guidance was raised to $62.0 billion to $64.0 billion, from $60.5 billion to $62.5 billion, and adjusted diluted earnings guidance to $2.95 to $3.05, from $2.80 to $3.00.

Who is Pfizer's new chief financial officer?
Cecile Guegan became permanent chief financial officer effective 1 November 2026, after serving as interim chief financial officer since 16 August.